Seeking Alpha

Citi initiates Clovis Oncology at Buy, big upside seen

  • Finally, someone on the sell-side is out talking about Clovis Oncology (CLVS) which rallied sharply (then faded a bit) Tuesday on reports it's exploring a sale.
  • Citi has initiated the shares at Buy.
  • Price target is $109, representing 45% worth of upside from Thursday's close.
  • CLVS +2.6% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector